Difference between revisions of "Enasidenib (Idhifa)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 18: | Line 18: | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
| − | |||
[[Category:IDH2 inhibitors]] | [[Category:IDH2 inhibitors]] | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
Revision as of 22:18, 11 August 2018
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).[1]
Diseases for which it is used
History of changes in FDA indication
- 8/1/2017: Granted FDA regular approval "for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Also known as
- Code names: AG-221, CC-90007
- Brand name: Idhifa